Details of the Drug

General Information of Drug (ID: DMD39G4)

Drug Name

Lintuzumab

Synonyms

Zamyl; HuM195; HuM195, PDL; Humanized M195, PDL; KB-195; SGN-33; SMART M195, PDL; M195 (humanized), Protein Design Labs; Anti-CD33 mAb (leukemia), Seattle Genetics

Indication

Disease Entry	ICD 11	Status	REF
leukaemia	2A60-2B33	Discontinued in Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

DrugBank ID: DB14877
TTD ID: D01RNL

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Myeloid cell surface antigen CD33 (CD33)	TTJVYO3	CD33_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

leukaemia

ICD Disease Classification

2A60-2B33

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Myeloid cell surface antigen CD33 (CD33)	DTT	CD33	5.37E-13	0.58	1.13

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7983).
2	Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005 Jun 20;23(18):4110-6.